AI주식인사이트AI Stock Insight
B

바이젠셀

308080KOSDAQ자연과학 및 공학 연구개발업

56.2 / 100

Reference Date: 2026-06-10

Financial Score13.0 / 40
News Sentiment20.2 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Declined 6.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bizen Cell is a biotech venture company established in 2013, specializing in the development and manufacturing of immunotherapy drugs. Leveraging its HLA research expertise and utilizing umbilical cord blood-derived immune therapies, the company is advancing as a cell therapy specialist through pipelines such as ViTier and ViMedier, while expanding into global new drug development and advanced regenerative medicine.

Number of Employees

43people

Average Salary

86.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
—Industry Average 3.243.5Point
ROE
-32.09Industry Average -32.093.5Point

In line with industry avg

Debt Ratio
20.24Industry Average 7.310.0Point

2.8x industry avg (risky)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼91.9% (1-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲6.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -25.3% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Detailed Momentum

52-week position5.0Point

52w mid range (54%)

Current 9,830Won52-week high 15,80052-week low 2,805
1-month return2.0Point

1m -6.56% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-14